Navigation Links
An international study identifies new DNA variants that increase the risk for cancer
Date:3/27/2013

Benítez concludes: "Every tumour is born with its own distinct genetic history, so if we identify those individuals whose genetic characteristics confer them a greater probability of developing cancer, we will be able to provide them with more adequate follow-up and thus reduce the appearance of the disease or diagnose it in its initial phases."

The collaborative effort of thousands of national and international scientists has opened new perspectives for cancer research, offering new clues to the understanding of the molecular pathways in cancer cells. These studies could also expand the possibilities in the search for new therapeutic treatments against cancer.

The CNIO, in addition to coordinating the genotyping of tumours, has also taken part in the genotyping of breast cancer studies via the National Genotyping Centre-Instituto de Salud Carlos III (CeGen-ISCIII), in collaboration with Anna González-Neira, Head of the Human Genotyping- CEGEN Core Unit as well as in the corresponding data analysis with the help of Roger Milne from the Human Genetics Group and Ana Osorio from the Genetic and Molecular Epidemiology Group. This work has been made possible thanks to the collaboration of the Monte Naranco hospital in Oviedo and the La Paz hospital in Madrid.

About COGS

The main aims of the European COGS project are directed towards the study of the genetic and environmental factors that predispose people to the appearance of breast, prostate and ovarian cancers, the most common forms of cancer in developing countries, and towards how society might benefit from such results.

The European COGS project is the result of the collaboration between four international consortiums: BCAC, whose aim is to study breast cancer; PRACTICAL, which researches genetic alterations associated with prostate cancer; OCAC, whose aim is to study ovarian cancer, and CIMBA, which studies BRCA1 and BRCA2 modifications.'/>"/>

Contact: Nuria Noriega
comunicacion@cnio.es
Centro Nacional de Investigaciones Oncologicas (CNIO)
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. International breast health global summit will focus on supportive care and quality of life
2. International conference to explore health of descendants of transatlantic slave trade
3. Kessler Foundation researchers present at first International Congress on Cognition in MS
4. Internationally known expert in ovarian cancer to be honored at the ASCO Annual Meeting
5. Nobel laureate to keynote international pharmaceutical conference at URI
6. International Nanomedicine Conference bound for Sydney: July 2-4, 2012
7. June 2012 marks a milestone for International Urogynecology Associates as Dr. Robert D. Moore and Dr. John R. Miklos perform their 24th Neovagina Surgery in 24 months
8. Heavy Duty Alternators and Starters Expert Elreg Distributors Ltd. Meets Needs of International Market with Launch of Spanish Website
9. The US Drug Watchdog Now Urges Plaintiffs Law Firms Worldwide To Contact Them About A Possible International Effort To Help Victims Of Defective Drugs Or Medical Devices
10. RMAX International to donate Recuper8 - a free, health - restoring program to Everyone in Uniform
11. International symposium on veterinary rehabilitation and physical therapy to be held in Vienna
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2014)... Va., April 23, 2014 The American Society for ... "The Role of Postoperative Radiation Therapy for Endometrial ... use of adjuvant radiation therapy in the treatment ... published in the May-June 2014 issue of ... practice journal of ASTRO. The full-length guideline is ...
(Date:4/23/2014)... researchers have developed a way to detect and measure ... gold particles with tails of synthetic DNA., A team ... engineering, used gold nanoparticles to target and bind to ... splice variants, which can indicate the presence and stage ... variants in a cell can be determined by examining ...
(Date:4/23/2014)... compound that targets an important brain receptor has a ... including relapse behavior, a University at Buffalo animal study ... this may be a novel lead compound for treating ... UB research was published as an online preview article ... study, the compound, RO5263397, severely blunted a broad range ...
(Date:4/23/2014)... New Rochelle, NY, April 23, 2014Men whose testosterone falls ... dysfunction and to be overweight and have heart disease ... designed to identify testosterone-deficient men for further testing and ... Journal of Men,s Health , a peer-reviewed publication from ... free on the Journal of Men,s Health ...
(Date:4/23/2014)... In science, "simple and accessible detection methods that ... the resolution of a single cell inside that ... chemical engineer Chang Lu. , In the Royal ... Lu has announced that he and his coworkers ... subcellular location of a protein ( Chem. Sci. ...
Breaking Medicine News(10 mins):Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3Health News:Gold nanoparticles help target, quantify breast cancer segments in a living cell 2Health News:Novel compound halts cocaine addiction and relapse behaviors 2Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2
... , SAN DIEGO, Dec. 2 US Farms, ... and Wellness products, is pleased to announce it will be ... Calif., at the Oakland Zoo on December 11-20, 2009. , ... at 877-90-FARMS or visit http://cookswareafaire.com , Victor Brandstetter, ...
... , American Red Cross also ... WASHINGTON, Dec. 2 The Hewlett-Packard Company Foundation has contributed ... Red Cross disaster response. , (Logo: http://www.newscom.com/cgi-bin/prnh/20090108/RedCrossLOGO ) ... Philippine communities affected by typhoons in September and October. Other ...
... , , NASHVILLE, Tenn., Dec. 2 ... development company, has appointed Pearson Talbert as chief development ... Talbert will provide leadership and vision to the sales ... help hospitals grow revenues through employer partnerships and physician ...
... , BELLEVUE, Wash., ... leading online retailer of health, beauty, vision and pharmacy products ... China, India, and Brazil, plus 50 additional countries worldwide. More ... beauty and wellness products on http://international.drugstore.com with pricing ...
... the gene could be linked to life span in males ... affect life span in humans and other mammals and could ... Japanese scientists say. , The researchers found that mice created ... average of 186 days longer than mice created from the ...
... not advised, expert says , WEDNESDAY, Dec. 2 (HealthDay ... their heart might be helping their eyes as well. ... what they described as a modest benefit for aspirin ... that destroys sharp, central vision. , "The data indicate ...
Cached Medicine News:Health News:US Farms, Inc. Showcasing Aloe365(TM) Product Line at Cook'sware A'faire at Oakland Zoo 2Health News:Hewlett-Packard Company Foundation Donates $1 Million for Red Cross Disaster Response 2Health News:Hewlett-Packard Company Foundation Donates $1 Million for Red Cross Disaster Response 3Health News:Aegis Health Group Hires Pearson Talbert as Chief Development Officer 2Health News:drugstore.com Continues Global Sales Expansion to More Than 3.5 Billion International Consumers 2Health News:Sperm Gene May Cause Men's Longevity Disadvantage 2Health News:In Women, Aspirin Might Ward Off Eye Trouble 2
(Date:1/15/2014)... (the "Company") (NASDAQ: CLSN ) today announced ... purchase an aggregate of approximately $15 million of the ... led by a dedicated health care fund. ... investors pursuant to which the Company agreed to sell ...
(Date:1/15/2014)... Jan. 15, 2014  Manufacturers, suppliers and distributors of ... to protect their most important business assets, intellectual ... ) Because of the highly-competitive nature ... one of the most litigious industry sectors of ...
(Date:1/15/2014)... , Jan. 15, 2014 The Cadence Fitness & ... Center by the Medical Fitness Association, a non-profit organization ... their full potential. The Cadence Fitness & Health Center ... suburbs and second in the Chicagoland area. ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Intellectual Property Insurance for Medical-related Products and Services 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3
... Cystic Fibrosis Society Conference, MONMOUTH JUNCTION, N.J., ... from a Phase II clinical trial on its ... is being developed for the treatment of cystic ... the bacterium Pseudomonas,aeruginosa. The Phase II data indicated ...
... Conn., June 13 VION,PHARMACEUTICALS, INC. (Nasdaq: ... conducted Phase II trial of its lead anticancer ... (AML) and high-risk myelodysplastic syndromes (MDS) had been,presented ... Association (EHA),at the Bella Center in Copenhagen, Denmark. ...
Cached Medicine Technology:Transave Announces Positive Phase II Results for Once-Daily Arikace(TM) in the Treatment of Cystic Fibrosis Patients Who Have Pseudomonas Lung Infections 2Transave Announces Positive Phase II Results for Once-Daily Arikace(TM) in the Treatment of Cystic Fibrosis Patients Who Have Pseudomonas Lung Infections 3Transave Announces Positive Phase II Results for Once-Daily Arikace(TM) in the Treatment of Cystic Fibrosis Patients Who Have Pseudomonas Lung Infections 4Transave Announces Positive Phase II Results for Once-Daily Arikace(TM) in the Treatment of Cystic Fibrosis Patients Who Have Pseudomonas Lung Infections 5Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting 2Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting 3Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting 4
5.5 mm disk shape burr. Diamond coated tip. Use with E0824 B handle....
Taper with blunt tip. Stainless steel. Round knurled handle with polished finish. Taper : Medium 23 mm. Overall length: 3.9 inches....
Abrupt taper 2 mm from the end, then more gradual taper so that quick dilation of the punctum is obtained. Stainless steel. Round knurled with polished finish. Overall length: 5.5 inches....
Double ended dilator probes with gentle curve. Stainless steel. Round knurled handle with polished finish. Overall length: 5.3 inches....
Medicine Products: